Announcement on Convening the Q3 2025 Performance Briefing
Filed with SSE · · 2 pages · Chinese
Sichuan Huiyu Pharmaceutical Co. Ltd. on 6ix
Earlier from Sichuan Huiyu Pharmaceutical
- Announcement on Participation of the Company and Its Related Parties in Private Equity Fund Investment and Related Party Transaction
- Announcement on Voluntary Disclosure of Prospective Winning in the National Centralized Drug Procurement
- Announcement on Judicial and Rotary Freezing of Shares Held by Shareholder with Over 5% Shares
- Announcement on Progress in Providing Guarantees for Wholly-owned Subsidiary
- Announcement on Intending to Provide Guarantee for Wholly-owned Subsidiaries
Later from Sichuan Huiyu Pharmaceutical
- Announcement on Obtaining Drug Registration Certificate for Etoposide Injecton
- Announcement on Voluntary Disclosure of the Acceptance of IND Application for the Drug Combination Involving HYP-6589 Tablets
- Announcement on Cooperation with Professional Institutions to Invest in the Establishment of a Private Equity Fund
- Announcement on Obtaining Drug Registration Certificate for Nicardipine Hydrochloride Injection
- Announcement on Progress in Participation in Private Equity Fund Investment and Related Party Transaction
Follow Sichuan Huiyu Pharmaceutical into a list and get an email when it puts out news.
Follow Sichuan Huiyu Pharmaceutical